As of February 2016, inviCRO has purchased MNI (Molecular Neuroimaging), a recognized leader in neurological-focused imaging and drug development. Now, with the exciting expansion of capabilities, inviCRO can provide a wide array of clinical imaging services through MNI as a division of inviCRO.
The research scientists and physicians at MNI have a unique capability in radioligand development and use of radioligands to establish target engagement in early clinical trials. We are proud to support the work of their internationally recognized team, and will together develop and execute large-scale clinical imaging trials for diagnosis, progression, and disease monitoring to support radiopharmaceutical and Phase 2-3 pharmaceutical development. Read more about MNI here.